Rallybio (RLYB) announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue